Prostate cancer
Conditions
Interventions
Experimental group:abiraterone +/- docetaxel
Control group:None
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 78 Years
Inclusion criteria
Inclusion criteria: 1. Prostate acinar adenocarcinoma was diagnosed by prostate biopsy , the clinical stage was locally advanced prostate cancer (pelvic MRI + whole body bone scan to evaluate the clinical stage), CT3a-CT4N0M0 or any CT, N1, M0; 2. Aged 10 years, plan to undergo radical prostatic cancer resection, without obvious surgical contraindications; 4. ECOG score = 90g/L, white blood cells >=3.5 x 10^9/L, and neutrophils >=1.5 x 10^9/L, platelets >=100 x 10^9/L; (2) Creatinine <= 1.0 x upper limit of normal (UNL); and the creatinine clearance rate is greater than 50ml/min; (3) Alanine aminotransferase (ALT) <= 1.5 x upper limit of normal (UNL); Aspartate amino transferase (AST) <= 1.5 x upper limit of normal (UNL); alkaline phosphatase (ALP) <= 1.5 x normal Upper limit (UNL); (4) Total bilirubin (TBIL) <= 1.5 x upper limit of normal (UNL); 6. Cooperate with treatment and follow-up regularly; 7. Sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. There are serious cardiopulmonary and other related diseases, and cannot tolerate surgery or neoadjuvant abiraterone, neoadjuvant chemotherapy or neoadjuvant ADT; 2. Combined with bone or visceral metastasis (M1); 3. Complicated with the following diseases: autoimmune diseases, severe cardiovascular and cerebrovascular diseases, vascular embolism related diseases, severe lung diseases, mental diseases; 4. Suspected or true history of alcohol or drug abuse; 5. Patients who are allergic to abiraterone or docetaxel; 6. Patients who have participated in other clinical trials within the past 3 months; 7. The investigator believes that the patient is not suitable to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| post-operative biochemical progression free survival; | — |
Countries
China
Contacts
Public ContactWang Xuan
Beijing Hospital
Outcome results
None listed